ArticleOncogene2021
LIMK1 promotes peritoneal metastasis of gastric cancer and is a therapeutic target.
Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 69 citations in OpenAlex.
- Prognostic Value of Systemic Inflammatory Markers in Predicting Peritoneal Metastasis in Gastric and Gastroesophageal Junction Cancer.Clinical and translational science · 2026Observational
- Extracellular vesicle-mediated GALNT1/RPRD1A glycosylation axis drives immune escape and peritoneal metastasis in gastric cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- Article
- LIMK1 is a prognosis and treatment biomarker in hepatocellular carcinoma.Scientific reports · 2025Article
- LIMK1 as a Novel Kinase of β-Catenin Promotes Esophageal Cancer Metastasis by Cooperating With CDK5.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity.Experimental hematology & oncology · 2025Article
- Molecular mechanisms of metastatic peritoneal dissemination in gastric adenocarcinoma.Cancer metastasis reviews · 2025Review
- Identification of LIMK1 as a biomarker in clear cell renal cell carcinoma: from data mining to validation.Journal of cancer research and clinical oncology · 2025Article
- Design, optimization, and ADMET evaluation of S11a-0000168202: A promising LIMK1 inhibitor for gastric cancer treatment.PloS one · 2025Article
- Case Report: Acute kidney injury due to minimal dilated obstructive nephropathy in the context of gastric cancer.Frontiers in oncology · 2025Article
- Targeting SNCA in the treatment of malignant ascites in gastrointestinal cancer.Translational oncology · 2024Article
- Article
- Significance of dysregulated M2 macrophage andTranslational cancer research · 2024Article
- Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer.World journal of gastrointestinal oncology · 2024Review
- Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells.Cell communication and signaling : CCS · 2024Article
- Detection of CDH1 gene promoter hypermethylation in gastric cancer and chronic gastritis.Practical laboratory medicine · 2024Article
- [Screening of differentially expressed genes in gastric cancer based on GEO database and function and pathway enrichment analysis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Developing a prognosis and chemotherapy evaluating model for colon adenocarcinoma based on mitotic catastrophe-related genes.Scientific reports · 2024Article
- Helicobacter pylori-activated fibroblasts as a silent partner in gastric cancer development.Cancer metastasis reviews · 2023Review
- Caveolin-1 mediates the utilization of extracellular proteins for survival in refractory gastric cancer.Experimental & molecular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal metastasis is a common form of metastasis among advanced gastric cancer patients. In this study, we reported the identification of LIM domain kinase 1 (LIMK1) as a promoter of gastric cancer peritoneal metastasis, and its potential to be a therapeutic target of dabrafenib (DAB). Using transcriptomic sequencing of paired gastric cancer peritoneal metastasis, primary tumors, and normal gastric tissues, we first unveiled that LIMK1 is selectively up-regulated in metastatic tumors. Increased LIMK1 in gastric cancer peritoneal metastasis was validated by immunohistochemistry analysis of an independent patient cohort. In vitro functional studies demonstrated that LIMK1 knockout or knockdown significantly inhibited cell migration and invasion of gastric cancer cells. LIMK1 knockout also abrogated peritoneal and liver metastases of gastric cancer cells in nude mice in vivo. Dabrafenib, a small molecule targeting LIMK1, was found to decrease cell migration and invasion of gastric cancer cells in vitro and abolish peritoneal and liver metastasis formation in vivo. Mechanistically, either LIMK1 knockout or Dabrafenib inhibited LIMK1 expression and phosphorylation of its downstream target cofilin. Taken together, our results demonstrated that LIMK1 functions as a metastasis promoter in gastric cancer by inhibiting LIMK1-p-cofilin and that Dabrafenib has the potential to serve as a novel treatment for gastric cancer peritoneal metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.